Dynamic changes in peripheral blood lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in metastatic osteosarcoma - Takeaways - MDSpire

Dynamic changes in peripheral blood lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in metastatic osteosarcoma

  • By

  • Longqing Li

  • Jinlei Liu

  • Yuan Zhao

  • Songtao Pang

  • Bin Zhang

  • Jia Wen

  • Yongkui Liu

  • Yi Zhang

  • Yan Zhang

  • Jiazhen Li

  • Nan Zhou

  • Xinchang Lu

  • May 13, 2026

  • 0 min

Share

  • 1

    Osteosarcoma is the most common primary malignant bone tumor in children and adolescents, with poor outcomes in metastatic cases.

  • 2

    Immune checkpoint inhibitors have variable efficacy in metastatic osteosarcoma, highlighting the need for predictive biomarkers.

  • 3

    Increased levels of specific peripheral blood lymphocyte subsets are associated with improved overall survival and treatment response.

  • 4

    Dynamic changes in CD3−CD56+ and CD8+HLA-DR+ cells post-ICIs correlate significantly with better clinical outcomes.

  • 5

    The presence of extrapulmonary metastasis is a significant risk factor for unfavorable overall survival in metastatic osteosarcoma.

Original Source(s)

Dynamic changes in peripheral blood lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in metastatic osteosarcoma

  • by Longqing Li, Jinlei Liu, Yuan Zhao, Songtao Pang, Bin Zhang, Jia Wen, Yongkui Liu, Yi Zhang, Yan Zhang, Jiazhen Li, Nan Zhou, Xinchang Lu

  • May 13, 2026

Related Content

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation